Why the study?
Is the myospryn K2906N polymorphism associated with left ventricular diastolic dysfunction in patients with high blood pressure?
Is the myospryn K2906N polymorphism associated with left ventricular diastolic dysfunction in patients with high blood pressure?
The myospryn K2906N polymorphism is significantly associated with left ventricular diastolic dysfunction in hypertensive patients, suggesting a potential novel therapeutic target for cardiac adaptation to pressure overload.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for myospryn variant in hypertensive diastolic dysfunction; requires prospective validation before clinical consideration.
BACKGROUND: With aging, left ventricle diastolic dysfunction due to pressure overload is an independent risk factor for morbidity and mortality. Mechanisms by which alterations in stretch-induced mechanotransduction contribute to left ventricular diastolic dysfunction remain unclear. Recently, since novel Z-disc related protein, myospryn, expressed in striated muscle cells, has been reported, we examined the relationship between myospryn polymorphisms and alterations in cardiac function with patients in larger population.METHODS: A total of 743 patients with high blood pressure (defined as systolic blood pressure >140 mmHg and/or systolic blood pressure >90 mmHg or taking antihypertensive medication) were enrolled in this study. Two-dimensional ultrasound echocardiography, electrocardiography, blood pressure, serum glucose, cholesterol, creatinine, uric acid, and myospryn K2906N polymorphism.RESULTS: The myospryn K2906N polymorphism was significantly associated with a marker of left ventricular diastolic cardiac dysfunction, A/E, which represents the ratio of the peak velocity of the early diastolic filling wave (E wave) to the atrial filling (A wave).CONCLUSIONS: These data demonstrated that a polymorphism of myospryn was associated with left ventricular diastolic dysfunction in hypertensive patients and provided the novel therapeutic target for cardiac adaptation in response to pressure overload as an anti-aging therapy.
No takes yet. Share an insight, caveat, or question.
Kikuchi et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: